Five Prime's pipeline includes potentially first-in-class anti-FGFR2b antibody bemarituzumab
Move comes after recommendation from independent data and safety monitoring board
Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021
Country's Health Ministry also recommended extending gap between doses to 12 weeks
Late-stage trial results found vaccine gives 91.6% protection against COVID-19